FY2029 Earnings Estimate for TENX Issued By Leerink Partnrs

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for Tenax Therapeutics in a note issued to investors on Tuesday, February 4th. Leerink Partnrs analyst D. Risinger forecasts that the specialty pharmaceutical company will post earnings per share of $0.63 for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share.

Several other research firms also recently weighed in on TENX. Guggenheim initiated coverage on Tenax Therapeutics in a research note on Monday, October 14th. They issued a “buy” rating and a $16.00 price target for the company. Leerink Partners initiated coverage on shares of Tenax Therapeutics in a research note on Thursday, October 24th. They set an “outperform” rating and a $16.00 target price for the company. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Tenax Therapeutics Trading Up 0.7 %

NASDAQ:TENX opened at $5.99 on Wednesday. The stock has a 50-day moving average price of $6.05 and a 200 day moving average price of $4.71. Tenax Therapeutics has a 12-month low of $2.77 and a 12-month high of $21.46.

Institutional Investors Weigh In On Tenax Therapeutics

Large investors have recently bought and sold shares of the business. Vestal Point Capital LP purchased a new position in shares of Tenax Therapeutics in the 3rd quarter worth $288,000. Stonepine Capital Management LLC bought a new position in shares of Tenax Therapeutics in the 3rd quarter valued at about $173,000. Finally, Sphera Funds Management LTD. purchased a new position in Tenax Therapeutics in the third quarter worth about $101,000. Institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.